Bellicum Pharmaceuticals completed its IPO Thursday, listing on the NASDAQ under the symbol BLCM. The company priced 7.35 million shares at $19 (above its range), raising almost $140 million. The early stage biotech debuted on the secondary market at $24.56, eventually closing the day at $23.88 with a market cap of around $600 million. Bellicum has raised $130 million in VC during 2014, including a $94 million round closed in September at a $196 million valuation. VC backers include Baker Biotech Capital (19.4% pre-IPO stake), McGuyer Investments (14.7%) and Remeditex Ventures (12.1%).